Atara Biotherap Cmn (ATRA) 19.17 $ATRA Atara Bi
Post# of 273242
Posted On: 09/19/2016 11:14:27 PM
Atara Biotherap Cmn (ATRA) 19.17 $ATRA
Atara Bio to Participate in the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 08, 3:05PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 1:05 p.m. ET. The conference will be held at The Grand Hyatt Hotel in New York, NY.
ATRA: 19.17 (-0.13), MS: 31.60 (+0.01)
Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today reported financial results for the second quarter ended June 30, 2016 and recent operational highlights.
ATRA: 19.17 (-0.13)
Atara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Thu Aug 04, 3:12PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Christopher Haqq, M.D., Ph.D., the Company's Chief Medical Officer, will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 9:00 a.m. ET. The conference will be held at The InterContinental Boston Hotel in Boston, MA.
ATRA: 19.17 (-0.13)
Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)
GlobeNewswire - Thu Jun 23, 8:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA has classified the Company's EBV-CTL product candidate as an Advanced Therapy Medicinal Product (ATMP) that falls within the definition of a somatic cell therapy medicinal product. Atara's EBV-CTLs are under development for the treatment of patients with EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD).
ATRA: 19.17 (-0.13)
Atara Bio to Present at the JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 3:05PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 9:00 a.m. ET. The conference will be held at The St. Regis New York Hotel in New York, NY.
ATRA: 19.17 (-0.13)
Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate
GlobeNewswire - Mon Jun 06, 5:30PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life threatening diseases that have been underserved by scientific innovation, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) reported clinical results for Atara's allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte (EBV-CTL) product candidate. Data were presented from an on-going Phase 2 clinical trial, which enrolled a heterogeneous group of EBV associated malignancies including NPC and post-transplant lymphoproliferative disorders, at an oral presentation at the ASCO 2016 Annual Meeting. This data included safety and efficacy of EBV-CTL in the treatment of 14 patients with recurrent metastatic nasopharyngeal carcinoma (NPC). EBV-associated NPC accounts for approximately 6,000 cases annually in the US and EU combined and approximately 80,000 cases worldwide. Historical median survival rates range from five to eleven months for patients with metastatic disease.
ATRA: 19.17 (-0.13)
Atara Bio to Present at Three Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present at three upcoming investor conferences in June:
ATRA: 19.17 (-0.13)
UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 6:25PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced presentations of clinical data from two of the Company's clinical-stage programs at the upcoming ASCO 2016 Annual Meeting, which will take place in Chicago, IL, June 3-7, 2016. The Company's collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will deliver clinical results in an oral presentation for Atara's allogeneic Epstein-Barr virus Cytotoxic T-Lymphocyte (EBV-CTL) product candidate in the treatment of patients with nasopharyngeal carcinoma (NPC). Also at ASCO, Atara will highlight in a poster presentation the initial clinical experience with the Company's molecularly targeted product candidate, STM 434, currently in an ongoing Phase 1 dose escalation trial in patients with ovarian cancer or other advanced solid tumors.
ATRA: 19.17 (-0.13)
Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:00PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced presentations of clinical data from two of the Company's clinical-stage programs at the upcoming ASCO 2016 Annual Meeting, which will take place in Chicago, IL, June 3-7, 2016. The Company's collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will deliver clinical results in an oral presentation for Atara's allogeneic Epstein-Barr virus Cytotoxic T-Lymphocyte (EBV-CTL) product candidate in the treatment of patients with nasopharyngeal carcinoma (NPC). Also at ASCO, Atara will highlight in a poster presentation the initial clinical experience with the Company's molecularly targeted product candidate, STM 434, currently in an ongoing Phase 1 dose escalation trial in patients with ovarian cancer or other advanced solid tumors.
ATRA: 19.17 (-0.13)
Atara Bio's Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress
GlobeNewswire - Mon May 09, 7:00AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that an oral presentation, entitled "Banked EBV-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma in Solid Organ Transplantation Recipients," will be delivered by the Company's collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) during the 2016 American Transplant Congress (ATC), taking place in Boston, MA, June 11-15, 2016. The presentation summarizes clinical experience with the Company's allogeneic Epstein-Barr virus cytotoxic T-Lymphocyte (EBV-CTL) product candidate for the treatment of patients with rituximab refractory EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) after solid organ transplant (SOT).
ATRA: 19.17 (-0.13)
Atara Biotherapeutics reports 1Q loss
Automated Insights - Thu May 05, 2:31PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $16.6 million in its first quarter.
ATRA: 19.17 (-0.13)
Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu May 05, 7:00AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today reported financial results for the first quarter ended March 31, 2016 and recent operational highlights.
ATRA: 19.17 (-0.13)
Atara Bio's Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
GlobeNewswire - Tue Apr 19, 4:15PM CDT
Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting
ATRA: 19.17 (-0.13)
Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 19.17 (-0.13), BXLT: 46.02 (-0.18), RDY: 46.99 (+0.24)
TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 0.95 (-0.02), MRK: 61.33 (-0.95), NVGN: 1.92 (+0.08), ATRA: 19.17 (-0.13), BMY: 55.08 (-0.52)
Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 12:40PM CST
Novo Nordisk (NVO) reported fourth quarter 2015 revenues that increased 2.3% year over year to $4.2 billion beating Zacks Consensus Estimate of $4.1 billion.
FATE: 3.00 (+0.08), NVO: 45.73 (-0.39), ATRA: 19.17 (-0.13), BXLT: 46.02 (-0.18)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 3.00 (+0.08), AMGN: 171.38 (-1.58), EPZM: 9.27 (-0.01), LLY: 79.16 (+0.36), ATRA: 19.17 (-0.13), GSK: 43.30 (+0.42), BMY: 55.08 (-0.52), ATNM: 1.65 (-0.03), CYCC: 5.48 (+0.08), BLCM: 19.44 (-0.43), BPTH: 1.41 (+0.02), CALA: 3.07 (+0.07), ABBV: 62.91 (-0.36), BXLT: 46.02 (-0.18), CBMG: 14.22 (-0.17)
Bio-Techne (TECH) Q2 Earnings Match, Sales Beat Estimates
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 11:40AM CST
Bio-Techne Corp. (TECH) reported adjusted earnings of 82 cents per share in the second quarter of fiscal 2016, in line with the Zacks Consensus Estimate.
TECH: 109.34 (+1.86), ATRA: 19.17 (-0.13), BXLT: 46.02 (-0.18), ANIK: 47.49 (+0.12)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 171.38 (-1.58), ATRA: 19.17 (-0.13), STML: 9.79 (-0.07), SNTA: 0.34 (+0.07), ATNM: 1.65 (-0.03), SNDX: 13.80 (-1.21), BLCM: 19.44 (-0.43), BPTH: 1.41 (+0.02), TEVA: 50.70 (-1.04), AGIO: 47.57 (+0.95), XLRN: 36.50 (+1.99), ARRY: 3.70 (+0.23)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 121.23 (-1.12), VICL: 3.00 (-0.86), CMRX: 5.54 (-0.02), PFE: 33.65 (-0.29), MRK: 61.33 (-0.95), ATRA: 19.17 (-0.13), VBIV: 3.89 (-0.07), GSK: 43.30 (+0.42), NVS: 79.94 (+0.60)
Atara Bio to Participate in the Morgan Stanley Global Healthcare Conference
GlobeNewswire - Thu Sep 08, 3:05PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 1:05 p.m. ET. The conference will be held at The Grand Hyatt Hotel in New York, NY.
ATRA: 19.17 (-0.13), MS: 31.60 (+0.01)
Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Mon Aug 08, 7:00AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today reported financial results for the second quarter ended June 30, 2016 and recent operational highlights.
ATRA: 19.17 (-0.13)
Atara Bio to Present at the Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Thu Aug 04, 3:12PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that Christopher Haqq, M.D., Ph.D., the Company's Chief Medical Officer, will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 9:00 a.m. ET. The conference will be held at The InterContinental Boston Hotel in Boston, MA.
ATRA: 19.17 (-0.13)
Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)
GlobeNewswire - Thu Jun 23, 8:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA has classified the Company's EBV-CTL product candidate as an Advanced Therapy Medicinal Product (ATMP) that falls within the definition of a somatic cell therapy medicinal product. Atara's EBV-CTLs are under development for the treatment of patients with EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD).
ATRA: 19.17 (-0.13)
Atara Bio to Present at the JMP Securities Life Sciences Conference
GlobeNewswire - Wed Jun 15, 3:05PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 9:00 a.m. ET. The conference will be held at The St. Regis New York Hotel in New York, NY.
ATRA: 19.17 (-0.13)
Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate
GlobeNewswire - Mon Jun 06, 5:30PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life threatening diseases that have been underserved by scientific innovation, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) reported clinical results for Atara's allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte (EBV-CTL) product candidate. Data were presented from an on-going Phase 2 clinical trial, which enrolled a heterogeneous group of EBV associated malignancies including NPC and post-transplant lymphoproliferative disorders, at an oral presentation at the ASCO 2016 Annual Meeting. This data included safety and efficacy of EBV-CTL in the treatment of 14 patients with recurrent metastatic nasopharyngeal carcinoma (NPC). EBV-associated NPC accounts for approximately 6,000 cases annually in the US and EU combined and approximately 80,000 cases worldwide. Historical median survival rates range from five to eleven months for patients with metastatic disease.
ATRA: 19.17 (-0.13)
Atara Bio to Present at Three Upcoming Investor Conferences
GlobeNewswire - Tue May 31, 3:05PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that Isaac Ciechanover, M.D., the Company's President and Chief Executive Officer, will present at three upcoming investor conferences in June:
ATRA: 19.17 (-0.13)
UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 6:25PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced presentations of clinical data from two of the Company's clinical-stage programs at the upcoming ASCO 2016 Annual Meeting, which will take place in Chicago, IL, June 3-7, 2016. The Company's collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will deliver clinical results in an oral presentation for Atara's allogeneic Epstein-Barr virus Cytotoxic T-Lymphocyte (EBV-CTL) product candidate in the treatment of patients with nasopharyngeal carcinoma (NPC). Also at ASCO, Atara will highlight in a poster presentation the initial clinical experience with the Company's molecularly targeted product candidate, STM 434, currently in an ongoing Phase 1 dose escalation trial in patients with ovarian cancer or other advanced solid tumors.
ATRA: 19.17 (-0.13)
Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Wed May 18, 4:00PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced presentations of clinical data from two of the Company's clinical-stage programs at the upcoming ASCO 2016 Annual Meeting, which will take place in Chicago, IL, June 3-7, 2016. The Company's collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will deliver clinical results in an oral presentation for Atara's allogeneic Epstein-Barr virus Cytotoxic T-Lymphocyte (EBV-CTL) product candidate in the treatment of patients with nasopharyngeal carcinoma (NPC). Also at ASCO, Atara will highlight in a poster presentation the initial clinical experience with the Company's molecularly targeted product candidate, STM 434, currently in an ongoing Phase 1 dose escalation trial in patients with ovarian cancer or other advanced solid tumors.
ATRA: 19.17 (-0.13)
Atara Bio's Collaborating Investigators to Present Clinical Data on EBV-CTL at 2016 American Transplant Congress
GlobeNewswire - Mon May 09, 7:00AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that an oral presentation, entitled "Banked EBV-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma in Solid Organ Transplantation Recipients," will be delivered by the Company's collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) during the 2016 American Transplant Congress (ATC), taking place in Boston, MA, June 11-15, 2016. The presentation summarizes clinical experience with the Company's allogeneic Epstein-Barr virus cytotoxic T-Lymphocyte (EBV-CTL) product candidate for the treatment of patients with rituximab refractory EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) after solid organ transplant (SOT).
ATRA: 19.17 (-0.13)
Atara Biotherapeutics reports 1Q loss
Automated Insights - Thu May 05, 2:31PM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $16.6 million in its first quarter.
ATRA: 19.17 (-0.13)
Atara Bio Announces First Quarter 2016 Financial Results and Recent Highlights
GlobeNewswire - Thu May 05, 7:00AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today reported financial results for the first quarter ended March 31, 2016 and recent operational highlights.
ATRA: 19.17 (-0.13)
Atara Bio's Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
GlobeNewswire - Tue Apr 19, 4:15PM CDT
Results Highlighted in Oral Presentation at the 2016 American Association for Cancer Research (AACR) Annual Meeting
ATRA: 19.17 (-0.13)
Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 19.17 (-0.13), BXLT: 46.02 (-0.18), RDY: 46.99 (+0.24)
TapImmune Tackles Ovarian Cancer in Fast Track Phase II Clinical Trials
ACCESSWIRE - Tue Feb 09, 8:00AM CST
Fast Track Label and Orphan Drug Designation granted for Ovarian cancer indication following positive data; Phase II trials in TPIV 200 with a partner brings TapImmune closer to a $111.9 billion cancer drug market
CERU: 0.95 (-0.02), MRK: 61.33 (-0.95), NVGN: 1.92 (+0.08), ATRA: 19.17 (-0.13), BMY: 55.08 (-0.52)
Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 12:40PM CST
Novo Nordisk (NVO) reported fourth quarter 2015 revenues that increased 2.3% year over year to $4.2 billion beating Zacks Consensus Estimate of $4.1 billion.
FATE: 3.00 (+0.08), NVO: 45.73 (-0.39), ATRA: 19.17 (-0.13), BXLT: 46.02 (-0.18)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 3.00 (+0.08), AMGN: 171.38 (-1.58), EPZM: 9.27 (-0.01), LLY: 79.16 (+0.36), ATRA: 19.17 (-0.13), GSK: 43.30 (+0.42), BMY: 55.08 (-0.52), ATNM: 1.65 (-0.03), CYCC: 5.48 (+0.08), BLCM: 19.44 (-0.43), BPTH: 1.41 (+0.02), CALA: 3.07 (+0.07), ABBV: 62.91 (-0.36), BXLT: 46.02 (-0.18), CBMG: 14.22 (-0.17)
Bio-Techne (TECH) Q2 Earnings Match, Sales Beat Estimates
Zacks Equity Research - Zacks Investment Research - Wed Feb 03, 11:40AM CST
Bio-Techne Corp. (TECH) reported adjusted earnings of 82 cents per share in the second quarter of fiscal 2016, in line with the Zacks Consensus Estimate.
TECH: 109.34 (+1.86), ATRA: 19.17 (-0.13), BXLT: 46.02 (-0.18), ANIK: 47.49 (+0.12)
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 171.38 (-1.58), ATRA: 19.17 (-0.13), STML: 9.79 (-0.07), SNTA: 0.34 (+0.07), ATNM: 1.65 (-0.03), SNDX: 13.80 (-1.21), BLCM: 19.44 (-0.43), BPTH: 1.41 (+0.02), TEVA: 50.70 (-1.04), AGIO: 47.57 (+0.95), XLRN: 36.50 (+1.99), ARRY: 3.70 (+0.23)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 121.23 (-1.12), VICL: 3.00 (-0.86), CMRX: 5.54 (-0.02), PFE: 33.65 (-0.29), MRK: 61.33 (-0.95), ATRA: 19.17 (-0.13), VBIV: 3.89 (-0.07), GSK: 43.30 (+0.42), NVS: 79.94 (+0.60)
(0)
(0)Scroll down for more posts ▼